Quadlytics raises ¥600M Series B for epilepsy seizure-prediction device
What's the deal? Kyoto-based QuadlyticsDealroom has a profile for this one. Try Dealroom → has raised ¥600 million in a Series B round to develop a wearable medical device that warns epilepsy patients of seizures before they occur. The financing came from five investors via a mix of third-party allotment shares and convertible bonds, bringing the startup's cumulative funding to ¥1.32 billion.
Who's backing it? Participants included JP LIFE NEXT1, Samurai Growth Fund 1, NextG, XTech3, and OLtV Opportunity Fund. The money will fund research into heart-rate variability analysis, seizure-detection technology, and international expansion.
What's the endgame? Spun out of Kyoto University and Kumamoto University in 2018, Quadlytics is building a non-invasive system that uses a wearable ECG to monitor autonomic nervous changes and machine learning to flag anomalies. The aim is to warn patients minutes before a seizure — a shift from detection to prediction.
Why it matters: Epilepsy affects roughly 50 million people worldwide, according to the World Health Organization. About 30% of patients cannot fully control seizures through medication, leaving them at risk of injury and living with uncertainty.
What could go wrong? The device remains in development and has not been approved under Japanese law. The company is targeting an Australian launch in 2028, pursuing regulatory approval and NDIS reimbursement there before expanding to North America. It is running clinical research with Monash University and Alfred Hospital, with later US work tied to the Mayo Clinic Platform.
"Through this Series B round, we have taken a major step toward our vision of creating a future where humanity can live without fearing epileptic seizures," said chief executive officer Kohei Hayashi (translated from Japanese).
The signal: Existing cleared wearables detect seizures already underway, mostly convulsive events. Quadlytics is betting on prediction instead — a more ambitious clinical goal whose success hinges on prospective validation, regulatory approval, and reimbursement.
Read more: prtimes.jp
Image credit: Generated with Gemini
